
Jan 12 (Reuters) - WAVE Life Sciences Ltd WVE.O:
WAVE LIFE SCIENCES HIGHLIGHTS STRATEGIC PRIORITIES FOR 2026 AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE: ACCELERATING DEVELOPMENT OF WVE-007 (INHBE SIRNA) FOR OBESITY AND RAPIDLY ADVANCING RNA EDITING PORTFOLIO
WAVE LIFE SCIENCES: EXPECTS TO FILE CTA IN 2026 FOR WVE-008 IN U.S. AND EUROPE
WAVE LIFE SCIENCES : REMAINS ON TRACK TO FILE NDA IN 2026 TO SUPPORT ACCELERATED APPROVAL OF WVE-N531 WITH MONTHLY DOSING